PAVmed Inc.  ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business ...

Q4 2024 Earnings Call Transcript March 24, 2025 Lucid Diagnostics Inc. misses on earnings expectations. Reported EPS is ...

Lucid Diagnostics (LUCD) reports record test volumes and strategic milestones in Q4 2024. Learn how Medicare coverage & NCCN inclusion may fuel 2025 growth.

Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.23 per share a year ago. These ...

Reports Q4 revenue $1.197M vs $1.040M last year. “The Lucid team finished 2024 on a strong note and 2025-which promises to be a pivotal year-is ...

My Lucid Air Touring had a catastrophic drivetrain failure after just 392 miles of ownership, turning my $69,000 EV into an ...

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) is expected to be releasing its earnings data before the market opens on ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that ...

Lucid Diagnostics Inc.�(Nasdaq: LUCD)�("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, a ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that ...

Detailed price information for Lucid Diagnostics Inc (LUCD-Q) from The Globe and Mail including charting and trades.

A multi-site study, backed by an $8 million NIH grant, will evaluate the effectiveness of Lucid Diagnostics' EsoCheck and ...